Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
Admilparant is a potential first-in-class, orally administered, potent and selective lysophosphatidic acid receptor 1 antagonist.
read more
Lesions were completely healed after 28 days in 63% of patients taking the drug, compared to in 24% receiving another treatment.
read more
Solengepras is an adjunctive treatment for patients with Parkinson’s disease who suffer from motor fluctuations when taking levodopa or similar medications.
read more
There is a risk that the drug may trigger arrhythmias and result in serious cardiovascular events or seizures.
read more
The drug is an orally-available combination of azacitidine (currently approved for subcutaneous administration) and cedazuridine.
read more
Together the companies aim to increase market coverage, customer reach, and awareness of oral dosage formats,
read more
The phase 1-ready GLP-1/GIP dual receptor agonist has the potential to treat patients with obesity and type 2 diabetes.
read more
The oral drug will be available to adults and pediatric patients along with a comprehensive patient support system.
read more
The potent oral small molecule inhibitor uses selective targeting of FGFR2 to minimize off-isoform toxicities.
read more
The potent KRAS G12D (ON) inhibitor targets the most common RAS mutation in human cancers while being selective over KRAS wildtype cells.
read more
The drug, which is already approved for treating bipolar depression, demonstrated efficacy for reducing signs and symptoms of mania.
read more
The site is one of ten U.S. manufacturing sites announced since 2020.
read more
The oral drug is expected to reduce the risk of eGFR decline and end-stage kidney disease.
read more
This marks the second FDA approval for Inluriyo in less than a year, following its September 2025 approval as a monotherapy.
read more
Linistinib is the only small molecule in late-stage development for active thyroid eye disease.
read more